Literature DB >> 1185162

Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings).

W Birkmayer, P Riederer.   

Abstract

1. A Dopa-medication leads sometimes in Parkinsonian patients to a psychosis. 2. The diminished capacity of striatal dopaminergic neurons to store DA leads to a storage of DA in serotoninergic or noradrenergic neurons. 3. Extrastriatal noradrenergic and/or serotoninergic neurons are involved. 4. Dopaminergic receptors of the striatium are not involved because of a lack of kinetic response after L-Dopa application in Parkinsonian patients with akinetic crises. 5. Extrastriatal dopaminergic receptors of DA as "false transmitter" at serotoninergic receptors seem to be responsible for the production of psychotic symptoms, whereas noradrenaline is not responsible. Psychotic symptoms can be imagined to be triggered by a contact of a transmitter to a nonspecific receptor.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1185162     DOI: 10.1007/bf01663632

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  2 in total

1.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz; K Jellinger; F Seitelberger
Journal:  J Neurol Sci       Date:  1973-12       Impact factor: 3.181

2.  [L-tryptophan therapy of DOPA psychoses].

Authors:  W Birkmayer; E Neumayer
Journal:  Nervenarzt       Date:  1972-02       Impact factor: 1.214

  2 in total
  16 in total

Review 1.  Neuropsychiatric non-motor aspects of Parkinson's disease.

Authors:  B R Thanvi; S K Munshi; N Vijaykumar; T C N Lo
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

Review 2.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

Review 3.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.

Authors:  T Büttner; W Kuhn; T Müller; F L Welter; J Federlein; K Heidbrink; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 5.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 6.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

7.  Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.

Authors:  J L Tillerson; A D Cohen; J Philhower; G W Miller; M J Zigmond; T Schallert
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

Review 8.  Psychosis in Parkinson's disease.

Authors:  B R Thanvi; T C N Lo; D P Harsh
Journal:  Postgrad Med J       Date:  2005-10       Impact factor: 2.401

Review 9.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 10.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.